S4-E27.4 - Previewing EASL Congress 2023 with Louise Campbell: Frontline Screening

Send us Fan MailSurfing NASH extends its preview coverage of the upcoming EASL Congress with a three-part episode. This conversation continues on the theme of sessions and presentations of interest as anticipated by Louise Campbell alongside Roger Green. Louise begins by noting a poster on the causes of death in patients with NAFLD who presented on a spectrum of fibrosis stages at diagnosis. She goes on to note some fascinating conclusions of the study to tease links between liver disease and cardiovascular and extrahepatic cancer outcomes. Ultimately, Louise suggests that the evidence emerging strengthens her views on the need for stratifying NAFLD according to metabolic cardiovascular risk. From here Louise points to a presentation by friend of the podcast Cyrielle Caussy titled Systematic screening for NAFLD-related advanced fibrosis in high-risk population in diabetology using transient elastography: a prospective study. The second leg of this conversation focuses on the paper and its implications for effective use of FIB-4 and developing our understanding of segmenting patient populations.The world’s largest liver meeting takes place 21-24 June in Vienna with an international faculty of experts from over 200 institutions. The diverse program will feature 2500 abstracts and be a uniquely momentous occasion for developing multidisciplinary approaches aimed at putting a major dent in Fatty Liver disease. Stay tuned for more coverage and if you have any question or interests around the event, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected]’s episode is sponsored by HistoIndex, the first global company to provide stain-free, fully automated imaging solutions for visualizing and quantifying morphological and architectural features of fibrosis. HistoIndex couples breakthrough biophotonic technology with an AI-powered digital pathology system to provide consistent, high-throughput imaging in liver disease and cancer. The platform benefits clinical research and speeds development of drugs and diagnostics. For more information, visit www.histoindex.com.Stay Safe and Surf On!